KALA BIO, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
KALA BIO, INC. (KALA) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2022-03-29
- KALA BIO, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $0.00.
- KALA BIO, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $0.00.
- KALA BIO, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $0.00.
- KALA BIO, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-12 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-12 |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 |
| 2015-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |